GlaukosvsMerck & Company

GKOS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

GKOS

Glaukos Corporation

$243.25

Value $14.1B

-0.67%
GKOS's page

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

Glaukos (GKOS) has a market value of $14.1B and Merck & Company (MRK) $354B. Over the last year, with dividends, GKOS moved +170.2% and MRK +58.8%. Dividend yield: GKOS none, MRK 2.37%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    GKOS$14.1B

    MRK$354B

    MRK is 25 times GKOS

  • Revenue, 12 months

    GKOS$690M

    MRK$67.4B

    MRK is 98 times GKOS

  • Net income, 12 months

    GKOS-$170M

    MRK$2.5B

  • Operating margin

    GKOS-25.5%

    MRK–

  • ROIC

    GKOS-19.9%

    MRK3.9%

    23.8 points apart

  • P/E

    GKOS–

    MRK144.5

  • Dividend yield

    GKOS0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    GKOS+385.4%

    MRK+98.6%

    286.8 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

GKOS+385.4%

MRK+98.6%

20040020222023202420252026
Returns by period
PeriodGKOSWith dividendsMRKWith dividends
1 year since November 14, 2025+170.2%Price +170.2%+58.8%Price +54.3%
3 years since November 17, 2023+279.7%+56.0% a yearPrice +279.7%+54.4%+15.6% a yearPrice +40.9%
5 years since November 16, 2021+385.4%+37.2% a yearPrice +385.4%+98.6%+14.7% a yearPrice +70.5%
10 years since November 17, 2016+622.9%+21.9% a yearPrice +622.9%+225.1%+12.5% a yearPrice +139.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

GKOSGlaukosMRKMerck & Company

Valuation

GKOSMRK
Valuation
Price$243.25$143.37
Market value$14.1B$354B
Enterprise value (EV)$14.0B$399B
P/E–144.5
P/E, 5-year median–14.8
P/B19.77.9
EV/EBIT–83.7
Free cash flow yield0.3%4.2%

Results and growth

GKOSMRK
Results and growth
Revenue, 12 months$690M$67.4B
Net income, 12 months-$170M$2.5B
Free cash flow, 12 months$36M$14.7B
Earnings per share, 12 months-$2.95$0.98
Revenue growth, year on year32.3%1.3%
Revenue growth a year, past+17.7%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

GKOSMRK
Margins and returns on capital
Gross margin64.8%71.8%
Operating margin-25.5%–
Net margin-24.6%3.6%
ROIC-19.9%3.9%
ROE-24.3%5.2%

Balance sheet

GKOSMRK
Balance sheet
Cash$162M$9.7B
Total debt$105M$53.8B
Net debt / EBITDA–5.7
Interest cover-36.6×2.4×

Dividends and buybacks

GKOSMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: GKOS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Glaukos or Merck & Company?

By market value, Merck & Company ($354B) is about 25.1 times Glaukos ($14.1B), at today's prices.

How did GKOS and MRK stock do over the last 10 years?

Since November 17, 2016, GKOS's price moved +622.9% and MRK's +139.6%. With dividends: GKOS +622.9% (+21.9% a year), MRK +225.1% (+12.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, GKOS or MRK?

The dividend yield at today's price is none for Glaukos and 2.37% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Glaukos or Merck & Company?

Over the last twelve months, the net margin was -24.6% for Glaukos and 3.6% for Merck & Company, and the operating margin -25.5% and –. Revenue was $690M and $67.4B.

Which is the better investment, Glaukos or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.